# GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease

> **NCT03823404** · PHASE2,PHASE3 · COMPLETED · sponsor: **Cortexyme Inc.** · enrollment: 643 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** COR388 capsule
- **DRUG:** Placebo capsule

## Key facts

- **NCT ID:** NCT03823404
- **Lead sponsor:** Cortexyme Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-28
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 643 (ACTUAL)
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03823404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03823404, "GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03823404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*